Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

Thrombosis and Haemostasis

Volumn 117, Issue 3, 2017, Pages 580-588

  Jakubowski, Joseph A ^a   Hoppe, Carolyn C ^b   Zhou, Chunmei ^a   Smith, Brendan E ^a   Brown, Patricia B ^a   Heath, Lori E ^a   Inusa, Baba ^c   Rees, David C ^d   Small, David S ^a   Gupta, Neehar ^a   Yao, Suqin ^a   Heeney, Matthew M ^e   Kanter, Julie ^f  

^a ELI LILLY AND COMPANY   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiplatelet; Clinical trial; Platelets; Prasugrel; VerifyNow

Indexed keywords

HYDROXYUREA; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BRAIN HEMORRHAGE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; FEMALE; HUMAN; MALE; MEDICAL TECHNOLOGY; PHASE 3 CLINICAL TRIAL; PLATELET REACTIVITY; POINT OF CARE TESTING; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SICKLE CELL ANEMIA; THROMBOCYTE AGGREGATION INHIBITION; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; METABOLISM; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME; VASCULAR DISEASE;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE TESTING; PRASUGREL HYDROCHLORIDE; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TIME FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 85014416057     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-09-0731     Document Type: Article

References (21)

1. Serjeant GR. Sickle-cell disease. Lancet 1997; 350: 725-730.
2. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-194.
3. Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
4. Jakubowski JA, Zhou C, Small DS, et al. A Phase 1 Study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol 2013; 75: 1433-1444.
5. Jakubowski JA, Zhou C, Jurcevic S, et al. A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thromb Res 2014; 133: 190-195.
6. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicentre phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013; 6: 17-26.
7. Hoppe CC, Styles L, Heath LE, et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) Trial: a global phase 3 doubleblind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dosetitration strategy. Pediatr Blood Cancer 2016; 63: 299-305.
8. Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 2016; 374: 625-635.
9. Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite highlevel P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
10. Styles L, Heiselman D, Heath LE, et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol 2015; 37: 1-9.
11. Jakubowski JA, Payne CD, Li YG, et al. The use of the VerifyNow P2Y12 pointof-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost. 2008; 99: 409-415.
12. Effient (package insert). Indianapolis, IN: Eli Lilly and Company; 2016. Available at http://uspl.lilly.com/effient/effient.html#pi. Accessed August 10, 2016.
13. Collet JP, Cayla G, Cuisset T, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011; 161: 5.e5-12.e5.
14. Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J 2014; 168: 674-681.
15. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157: 818-824.e1.
16. Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 2008; 117: 553-559.
17. Wessel DL, Berger F, Li JS, et al. A randomized trial of clopidogrel to reduce mortality and shunt-related morbidity in infants palliated with a systemic to pulmonary artery shunt. Circulation 2010; 122: (21 Suppl).
18. Cabannes R, Lonsdorfer J, Castaigne JP, et al. Clinical and biological doubleblind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984; 15: 213-221.
19. Semple MJ, Al-Hasani SF, Kioy P, et al. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-306.
20. Gurbel PA, Bliden KP, Hiatt B, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
21. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.